NCT02889380View on ClinicalTrials.gov

A Retrospective Study in Chinese Good Prognosis Patients Undergoing Assisted Reproductive Technology (ART) Treatment

CompletedOBSERVATIONAL

Enrollment

3,000

Participants

Timeline

Start Date

August 29, 2016

Primary Completion Date

April 26, 2017

Study Completion Date

April 26, 2017

Conditions

Infertility

Interventions

DRUG

No Intervention

This study will retrospectively collect the data from the subjects who had been treated with 0.25 mg of Cetrotide injection daily in a fixed or flexible antagonist protocol with an available ART outcome.

Trial Locations (4)

Unknown

Peking University Third Hospital, Beijing

The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou

Reproductive Hospital Affiliated to Shandong University, Shandong

Reproductive & Genetic hospital of CITIC-XIANGYA, Xiangya

All Listed Sponsors

lead

Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT02889380 - A Retrospective Study in Chinese Good Prognosis Patients Undergoing Assisted Reproductive Technology (ART) Treatment | Biotech Hunter | Biotech Hunter